Teva Pharmaceutical Industries Limited American Depositary Shares

News & Events

Press Releases

In The Media

1. New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

   GlobeNewswire MAY 30, 2025 9:05 PM EDT
   More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) setting...
   READ ARTICLE

2. Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

   GlobeNewswire MAY 30, 2025 9:00 PM EDT
   Real-world claims studies evaluating UZEDY ® (risperidone) also show improved adhere...
   READ ARTICLE

3. Teva Reaffirms "Pivot to Growth" Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

   GlobeNewswire MAY 29, 2025 8:00 AM EDT
   Teva outlines acceleration path into a leading biopharma company Innovative medicines fra...
   READ ARTICLE

4. Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

   GlobeNewswire MAY 27, 2025 5:30 PM EDT
   Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designat...
   READ ARTICLE

5. Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

   GlobeNewswire MAY 27, 2025 4:30 PM EDT
   TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and ...
   READ ARTICLE

6. Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

   GlobeNewswire MAY 27, 2025 8:30 AM EDT
   BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammato...
   READ ARTICLE

7. Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

   GlobeNewswire MAY 22, 2025 1:56 PM EDT
   TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and ...
   READ ARTICLE

8. Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

   GlobeNewswire MAY 20, 2025 5:21 PM EDT
   TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and ...
   READ ARTICLE

9. Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

   GlobeNewswire MAY 20, 2025 4:30 PM EDT
   TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) ...
   READ ARTICLE

10. Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

    GlobeNewswire MAY 19, 2025 4:52 AM EDT
    TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and ...
    READ ARTICLE